A bipartisan coalition of Pennsylvania legislators, led by Representative Tarik Khan, has introduced House Bill 2711 — a sweeping proposal aimed at overhauling how pharmacy benefit managers (PBMs) operate within the state. The bill targets pricing transparency, rebate pass-throughs, and anti-competitive contracting practices that critics say have driven up prescription drug costs for consumers and squeezed independent pharmacies out of the market. If enacted, HB 2711 would position Pennsylvania among a growing number of states moving aggressively to rein in PBM conduct. The timing is notable: federal scrutiny of PBMs has intensified in parallel, with the FTC releasing a critical report on the sector in 2024.
What HB 2711 Means for Drug Pricing and Pharmacy Access in Pennsylvania
Before diving into the specifics, it helps to understand why this bill matters beyond Harrisburg. PBMs sit at the center of the pharmaceutical supply chain, negotiating drug prices between insurers, manufacturers, and pharmacies. Their influence over formulary placement, reimbursement rates, and rebate flows gives them enormous leverage. Yet that leverage has increasingly drawn bipartisan criticism for lacking accountability.
- Rebate transparency: HB 2711 would require PBMs to pass through 100% of manufacturer rebates to health plans and patients at the point of sale, eliminating a key revenue mechanism that critics argue inflates list prices
- Spread pricing ban: The bill prohibits PBMs from charging health plans more for a drug than what they reimburse pharmacies — a practice known as spread pricing that has generated significant margins for PBMs at the expense of payers
- Independent pharmacies would gain new protections against below-cost reimbursement and retroactive clawbacks, practices that have contributed to pharmacy closures across rural and underserved communities
- Licensure and oversight: PBMs operating in Pennsylvania would face new registration requirements and regulatory oversight, giving the state insurance department enforcement authority it currently lacks
- Anti-steering provisions: The legislation restricts PBMs from steering patients toward PBM-owned pharmacies, a vertically integrated practice that has drawn antitrust concerns nationally
The Vertical Integration Problem
Three companies control roughly 80% of the PBM market in the United States: CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (a UnitedHealth Group subsidiary). Each of these entities also owns or operates pharmacy chains, specialty pharmacies, and in some cases health insurance plans. That consolidation has created what some economists describe as a closed loop — where the same corporate entity negotiates the price, dispenses the drug, and adjudicates the claim.
Representative Khan and co-sponsors argue this structure creates inherent conflicts of interest. And while PBMs maintain they reduce costs through negotiating power, independent analyses have increasingly questioned whether those savings reach consumers. A 2024 FTC interim report found that the largest PBMs often steered patients toward their own affiliated pharmacies and retained significant portions of rebate revenue.
Pennsylvania’s legislative effort to regulate pharmacy benefit manager practices reflects a broader state-level trend. More than 30 states have enacted some form of PBM regulation in recent years, though the scope and enforcement mechanisms vary widely (a distinction regulators have been slow to standardize).
How Independent Pharmacies Stand to Benefit
The bill arrives at a precarious moment for independent pharmacy operators. According to the National Community Pharmacists Association, roughly 7.5% of independent pharmacies in the U.S. closed between 2022 and 2024, with below-cost PBM reimbursements cited as a primary driver. In rural Pennsylvania counties, some communities have already lost their only pharmacy.
HB 2711’s reimbursement floor provisions would, at least on paper, prevent PBMs from paying pharmacies less than their acquisition cost for medications. That single provision could alter the economics of pharmacy operation in underserved areas significantly. Still, whether enforcement mechanisms in the bill are robust enough to prevent workarounds remains an open question among pharmacy advocates.
Comparing PBM Reform Approaches Across Key States
| State | Rebate Pass-Through | Spread Pricing Ban | PBM Licensure Required | Anti-Steering Provisions |
|---|---|---|---|---|
| Pennsylvania (HB 2711) | Yes — 100% | Yes | Yes | Yes |
| Arkansas | Partial | Yes | Yes | Limited |
| West Virginia | Yes | Yes | Yes | Yes |
| Ohio | Yes — Medicaid only | Yes — Medicaid only | No | No |
| Texas | Under review | No | Yes | Partial |
Industry Response and What Comes Next
PBM industry groups have historically pushed back against state-level regulation, arguing it fragments the market and could raise costs for employers who self-insure across multiple states. The Pharmaceutical Care Management Association, the primary PBM trade group, has challenged similar laws in court — most notably in Arkansas, where a case reached the U.S. Supreme Court in 2020. The Court ruled in favor of state authority to regulate PBM reimbursement rates, a decision that arguably cleared the legal path for bills like HB 2711.
But legal precedent alone doesn’t guarantee smooth passage. Pennsylvania’s legislative calendar, committee dynamics, and lobbying pressure from PBM-aligned insurers will all shape the bill’s trajectory. Representative Khan has signaled bipartisan support, which matters in a state legislature where healthcare legislation often stalls along partisan lines.
What remains less clear is whether the bill will survive the committee process intact. Previous reform attempts in Pennsylvania were diluted through amendments that stripped key enforcement provisions before reaching a floor vote.
Why Framing Matters: The Psychology of Drug Pricing Reform
Public support for PBM regulation tends to spike when the issue is framed around tangible consumer harm rather than abstract market structure. Neuro-linguistic programming principles suggest that how legislators and advocates frame this debate will significantly influence its outcome. When patients hear that a middleman retained a portion of a rebate that could have lowered their copay, the response is visceral. When the same issue is described as “supply chain inefficiency,” engagement drops.
Effective advocacy around HB 2711 will likely lean into specific, concrete narratives: the diabetic patient paying $300 for insulin at a pharmacy that was reimbursed $250 by the PBM, while the PBM billed the insurer $400. That $150 spread isn’t theoretical. It represents a real margin extracted from a real transaction, and anchoring the debate in those terms changes how people process the information.
Cognitive anchoring also plays a role in legislative negotiation. By introducing a bill with comprehensive provisions — full rebate pass-through, complete spread pricing ban, mandatory licensure — sponsors set a high anchor point. Even if the final version includes compromises, the starting position shapes what “reasonable” looks like in committee discussions. Legislators who understand this dynamic tend to draft maximalist bills not because they expect full passage, but because the anchor itself moves the negotiation window.
Language specificity matters too. Terms like “clawback” and “spread pricing” carry different emotional weight than “reimbursement adjustment” or “pricing differential.” The bill’s sponsors appear to have chosen their terminology deliberately, opting for words that convey extraction rather than neutral market mechanics.
Frequently Asked Questions
What is a pharmacy benefit manager?
A PBM is a third-party administrator that manages prescription drug benefits on behalf of health insurers, employers, and government programs. They negotiate prices with manufacturers, determine which drugs are covered, and set reimbursement rates for pharmacies.
Does HB 2711 apply to all health plans in Pennsylvania?
The bill targets PBM conduct broadly within the state, though self-insured employer plans governed by federal ERISA law may fall outside its reach. That jurisdictional gap has been a persistent challenge for state-level PBM reform nationwide.
When could HB 2711 take effect?
The bill must pass through committee review, floor votes in both chambers, and the governor’s signature. No timeline has been confirmed, and the legislative process could extend well into 2025 or beyond depending on committee scheduling and amendment activity.
How does this compare to federal PBM reform efforts?
Several federal proposals are circulating in Congress, but none have advanced to a vote. State-level action like HB 2711 arguably fills a regulatory vacuum that federal inaction has left open.
